EL7.AI
StocksMedium•17 November 2026•
2 min read

Moderna shares fall 3.8% in morning trading as spending and trial concerns mount

Key Facts

1Moderna shares fell 3.8% in morning trading on November 17, 2026, and hit a session low of $212.50.
2Management projected annual cash costs of about $4 billion through 2027 and annual spending of between $4 billion and $4.5 billion through 2030, compared with $2.1 billion in 2025.
3Moderna postponed formal 2027 revenue guidance until its fourth-quarter earnings call.
4U.S. retail and food services sales totaled $748.2 billion in October, up 0.2% month over month and 6.8% year over year.

Moderna shares fell 3.8% in morning trading on November 17, 2026, hitting a session low of $212.50, according to Investing.com. The report linked the decline to company-specific concerns and weakness in growth stocks, without describing the move as a reflection of broad pressure on the healthcare sector. The drop came after management disclosed expectations for high cash spending over the coming years. An interim readout for its norovirus vaccine also failed to meet early statistical success criteria. The company postponed formal guidance for 2027 revenue until its fourth-quarter earnings call.

Moderna management projected annual cash costs of about $4 billion through 2027, and continued spending of between $4 billion and $4.5 billion annually through 2030. These levels represent a clear increase from the roughly $2.1 billion the company spent in cash in 2025, according to Investing.com’s account of the analyst day. This spending trajectory puts the scale of future outlays at the forefront of considerations for investors evaluating the company’s plans. Management has not yet provided formal guidance for 2027 revenue, and will postpone it until the fourth-quarter earnings call. This means revenue estimates for next year will remain undisclosed until that call.

On the development front, the interim analysis of Moderna’s Phase 3 norovirus vaccine did not meet early statistical success criteria, according to the report. In the broader market, U.S. stocks also fell on November 17, but losses were less severe than in the previous session, according to the Associated Press. The indexes had declined on November 16, with the S&P 500 down 1.9% and the Nasdaq down 2.5%, as weakness spread from technology stocks to other sectors. Separately, Census Bureau data showed retail and food services sales totaled $748.2 billion in October, up 0.2% month over month and 6.8% year over year; the revised September reading was 0.8%. The bureau set December 16, 2026, as the release date for its November report, while MSCI announced on November 11 that Moderna would be added to the MSCI World Index effective November 30.

Open on chart